Galectin Therapeutic (GALT)

$2.18 +0.01 (0.46%)
Market Cap 137.98M
Revenue (ttm) 0.00
Net Income (ttm) -47.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.68
Volume 239,400
Avg Vol 669,238
Day's Range N/A - N/A
Shares Out 63.29M
Stochastic %K 14%
Beta 0.70
Analysts Strong Sell
Price Target $6.00

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 620 3186
Address:
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States
Indibviduate1
Indibviduate1 Jul. 7 at 4:12 AM
$GALT
0 · Reply
Indibviduate1
Indibviduate1 Jul. 7 at 3:26 AM
$GALT things that could really make this an exciting week Ftd short forced to buy shares to cover short sold shares sold naked Overdue. 36 month data. Overdue 18 month Biodata. Announcement of a buyout Announcement of a partnership FDA coupon granted to the company for 4-8 week conditional approval
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jul. 7 at 12:36 AM
$GALT my word overnights I do declare you are giving me the vapors.
1 · Reply
johnhankowitz
johnhankowitz Jul. 6 at 11:47 PM
$GALT Looking forward to this week!
0 · Reply
MajorStockTradingLLC
MajorStockTradingLLC Jul. 6 at 10:38 PM
$GALT
0 · Reply
Matolemeu
Matolemeu Jul. 6 at 9:18 PM
$GALT is this that name-calling you were reporting Thomas for or...?
1 · Reply
th3_fail_k1ng
th3_fail_k1ng Jul. 6 at 8:49 PM
$GALT i am looking forward to Monday 🙂 had a chance to recharge the old battery and definitely ready to see some ftds and margin calls 😁
1 · Reply
Red1soxlover
Red1soxlover Jul. 6 at 8:36 PM
$GALT
0 · Reply
ThomasLD
ThomasLD Jul. 6 at 8:32 PM
$GALT you are a horrible human being. Blocked and reported.
1 · Reply
elmono
elmono Jul. 6 at 7:58 PM
$GALT I encourage all my followers to please report ThomasLD. I have been viciously and repeatedly attacked and insulted by him and a few others, after one twit I posted with my opinion. The person below is again continuing his insults by calling me trash. I have reported him and any other that started being offensive and insulting in the first place
1 · Reply
Latest News on GALT
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

May 12, 2025, 8:00 AM EDT - 7 weeks ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Jan 10, 2025, 8:00 AM EST - 6 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 10:29 AM EST - 7 months ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Dec 20, 2024, 8:00 AM EST - 7 months ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 18, 2024, 8:00 AM EST - 8 months ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Nov 14, 2024, 8:00 AM EST - 8 months ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Oct 15, 2024, 8:00 AM EDT - 9 months ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 10 months ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 13, 2024, 8:00 AM EDT - 11 months ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

May 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Mar 20, 2024, 8:11 PM EDT - 1 year ago

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Dec 7, 2023, 6:00 AM EST - 1 year ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:45 AM EST - 1 year ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Oct 12, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 26, 2023, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

Sep 14, 2023, 8:15 AM EDT - 1 year ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GLTO

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 13, 2023, 5:22 PM EDT - 1 year ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Sep 7, 2023, 12:00 PM EDT - 1 year ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 24, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 5, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 28, 2022, 8:00 AM EST - 2 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 14, 2022, 8:00 AM EST - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Nov 1, 2022, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Galectin Therapeutics to Present in Upcoming Conferences

Oct 14, 2022, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 12, 2022, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Oct 6, 2022, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Jul 26, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Galectin: Ability To Potentially Target Unmet Medical Need

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

May 23, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

May 16, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Jan 6, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Indibviduate1
Indibviduate1 Jul. 7 at 4:12 AM
$GALT
0 · Reply
Indibviduate1
Indibviduate1 Jul. 7 at 3:26 AM
$GALT things that could really make this an exciting week Ftd short forced to buy shares to cover short sold shares sold naked Overdue. 36 month data. Overdue 18 month Biodata. Announcement of a buyout Announcement of a partnership FDA coupon granted to the company for 4-8 week conditional approval
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Jul. 7 at 12:36 AM
$GALT my word overnights I do declare you are giving me the vapors.
1 · Reply
johnhankowitz
johnhankowitz Jul. 6 at 11:47 PM
$GALT Looking forward to this week!
0 · Reply
MajorStockTradingLLC
MajorStockTradingLLC Jul. 6 at 10:38 PM
$GALT
0 · Reply
Matolemeu
Matolemeu Jul. 6 at 9:18 PM
$GALT is this that name-calling you were reporting Thomas for or...?
1 · Reply
th3_fail_k1ng
th3_fail_k1ng Jul. 6 at 8:49 PM
$GALT i am looking forward to Monday 🙂 had a chance to recharge the old battery and definitely ready to see some ftds and margin calls 😁
1 · Reply
Red1soxlover
Red1soxlover Jul. 6 at 8:36 PM
$GALT
0 · Reply
ThomasLD
ThomasLD Jul. 6 at 8:32 PM
$GALT you are a horrible human being. Blocked and reported.
1 · Reply
elmono
elmono Jul. 6 at 7:58 PM
$GALT I encourage all my followers to please report ThomasLD. I have been viciously and repeatedly attacked and insulted by him and a few others, after one twit I posted with my opinion. The person below is again continuing his insults by calling me trash. I have reported him and any other that started being offensive and insulting in the first place
1 · Reply
Willie3000
Willie3000 Jul. 6 at 7:01 PM
$GALT 😎
0 · Reply
Kilarck
Kilarck Jul. 6 at 6:42 PM
$GALT https://talkmarkets.com/content/stocks--equities/galectin-therapeutics-is-undervalued-and-with-short-squeeze-underway?post=504960 Bullish
1 · Reply
Belapectin
Belapectin Jul. 6 at 6:38 PM
$GALT
0 · Reply
3ifs2nos
3ifs2nos Jul. 6 at 6:34 PM
$GALT 🦅
0 · Reply
Cincy_JFM
Cincy_JFM Jul. 6 at 5:54 PM
$GALT
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 6 at 3:03 PM
Money Monday Watchlist Pt. 5 $GALT $YHC $TZUP $KLTO $SBFM
1 · Reply
Indibviduate1
Indibviduate1 Jul. 6 at 2:46 PM
$GALT
0 · Reply
ThomasLD
ThomasLD Jul. 6 at 2:20 PM
$GALT One more post about @elmono . Everyone please stop chatting with this trash 🗑️. Do not even reply back to him. If he continues to post invalid data or anything that is against STOCKTWITS policies, PLEASE REPORT HIM. I have reported a few bad people here in the past and Stocktwits suspended their accounts. One of the accounts was banned forever.
1 · Reply
ThomasLD
ThomasLD Jul. 6 at 1:34 PM
$GALT CORRECTION
1 · Reply
Schuuultz
Schuuultz Jul. 6 at 12:49 PM
$GALT
0 · Reply
DividendHero69
DividendHero69 Jul. 6 at 11:44 AM
$GALT @elmono you were talking about completely different company and you call him noob? xD how much u shorted buddy? share ur position with us?
1 · Reply
elmono
elmono Jul. 6 at 11:05 AM
$GALT please don’t pay attention to a cheerleading wannabee…who doesn’t know how to read…..is obsessed with 1 ticker in which he likely put all his milk money. A true noob who has so much too learn….,so ignorant…..limited mental abilities….tough road ahead 😂😂😂🤷‍♂️
1 · Reply